The Macro Group UK Medal is awarded annually to a UK based scientist who has made a significant and substantial contribution to the development of polymer science through his/her scientific achievements and/or services to the UK polymer science community.
This year the award has been made to Professor Andrew Lewis, Director of Research & Development, Innovation, Biocompatibles UK Ltd, a BTG International group company, Professor of Biomaterials & Drug Delivery. Professor Lewis has experience of developing products within small, medium and large companies, having spent his early career with ICI working in the area of advanced polymer membranes and subsequently with Johnson & Johnson leading projects in absorbent technologies. Andy joined Biocompatibles in 1996 and is Director of R&D in Innovation (now part of BTG).
He specialises in the development of advanced biomedical polymer systems, for instance, to enhance the biocompatibility of implants or to modulate delivery of active agents in the body. These technologies have been applied to novel drug-device combination products for use in interventional therapies in the treatment of cardiovascular disease and cancer and have resulted in around a dozen products reaching commercialisation.
Andy has generated around 230 scientific peer-reviewed publications and articles (H-index 52), 11 book chapters and 50 patent families/applications in the fields of polymers, biomaterials and drug delivery. He is Professor of Biomaterials & Drug Delivery at the University of Brighton where he lectures on Drug-Device Combination Products and in 2015 was recognised by the scientific community with the award of the Chapman Medal for distinguished research in the field of biomedical materials, particularly with respect to biomaterials innovation, which has produced benefits for patients and/or contributed to associated opportunities for industry. In 2017 he was presented with the Royal Pharmaceutical Society Award for Excellence in Pharmaceutical Science for his contribution to the development of a Novel Drug-eluting Bead concept that had just entered clinical evaluation.